TG THERAPEUTICS, INC. Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31)
TG THERAPEUTICS, INC. (TGTX) had Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) of $4.00 million as of 2011-12-29, per its 10-K filed 2013-03-21.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionPurchasePriceAllocationAssetsAcquired · last filed 2013-03-21
- 2011-12-29: Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) $4.00M; Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) as first filed $5.54M.
| Period end | Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) | Business Acquisition, Purchase Price Allocation, Assets Acquired (Deprecated 2013-01-31) as first filed |
|---|---|---|
| 2011-12-29 | $4.00M 10-K · filed 2013-03-21 | $5.54M 10-Q/A · filed 2012-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |